Drug Profile
Zatolmilast - Tetra Therapeutics
Alternative Names: BPN-14770Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Tetra Discovery Partners
- Developer Tetra Therapeutics
- Class Acetamides; Amines; Antidementias; Benzeneacetamides; Chlorobenzenes; Fluorinated hydrocarbons; Pyrimidines; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease; Cognition disorders
Highest Development Phases
- Phase II/III Fragile X syndrome
- Phase II Alzheimer's disease
Most Recent Events
- 11 Apr 2024 Zatolmilast - Tetra Therapeutics receives Orphan Drug status for Fragile X syndrome in European Union
- 27 Sep 2023 Zatolmilast receives Rare Pediatric Disease Designation from the U.S. FDA for Fragile X syndrome in USA
- 13 Jul 2022 Phase-II/III clinical trials in Fragile X syndrome (In adults) in USA (PO), (NCT05358886)